fda compounding semaglutide news today May 4, 2026: FDA moves to restrict large-scale compounding of three weight loss drugs – Partnership for Safe Medicines

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

24.90

★★★★☆4.8 (126)

FDA issues warning about some compounded versions of semaglutide for diabetes, weight loss

20.30

★★★★★4.9 (98)

🚨 FDA Cracks Down on Compounded GLP-1s – What's Next for Weight Loss? 🚨 Big news in the weight loss world: The FDA is officially shutting down compounding pharmacies producing GLP-1 medications

25.70

★★★★★5.0 (157)

FDA Ends Semaglutide Shortage, Compounded GLP-1 Market

28.28

★★★★★4.7 (84)

FDA moves to remove GLP-1 medications from 503B Bulks List

27.47

★★★★★4.9 (203)

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

22.40

★★★★★5.0 (176)

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the

23.42

★★★★★4.8 (132)